- Teleflex ( NYSE: TFX ) is trading down ~8% after the company lowered its 2022 profit guidance and posted Q2 revenue that missed estimates due to slower-than-expected recovery in interventional urology business.
- The company lowered it adjusted diluted EPS from continuing operations guidance to $13.00 to $13.40 from $13.70 to $14.30. ($13.95 per share consensus )
- Revenue fell 1.3% Y/Y to $704.5M and missed estimates by $15M.
- Q2 Non-GAAP EPS of $3.39 beat by $0.05.
- Cash and cash equivalents at June 26 were $308.1M.
- Interventional Urology fell 13.5% Y/Y to $79.8M.
- Net Revenue for EMEA fell 7.6% Y/Y to $145.2M.
For further details see:
Teleflex down 8% on lower 2022 guidance, revenue miss